-
公开(公告)号：US11518808B2
公开(公告)日：2022-12-06
申请号：US16245733
申请日：2019-01-11
Applicant: AMGEN INC.
Inventor： Khaled M. K. Z. Ali , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Ian Foltz , Zhulun Wang , Daren Bates , Marissa Mock , Shunsuke Takenaka
IPC: C07K16/28 , A61P35/00 , A61K39/395 , C07K16/06 , C12N15/85
Abstract: Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.
-
公开(公告)号：US20190046611A1
公开(公告)日：2019-02-14
申请号：US16054035
申请日：2018-08-03
Applicant: AMGEN INC.
Inventor： Khaled M.K.Z. Ali , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Ian Foltz , Zhulun Wang , Darren Bates , Marissa Mock , Shunsuke Takenaka
Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
-
公开(公告)号：US12103979B2
公开(公告)日：2024-10-01
申请号：US16607673
申请日：2018-04-27
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish Agrawal , Pavan Ghattyvenkatakrishna , Sekhar Kanapuram , Christopher James Sloey
IPC: A61K39/395 , A61K9/08 , A61K9/19 , A61K31/198 , A61K31/401 , A61K31/4172 , A61K38/05 , A61K47/18 , A61K47/26 , C07K5/06 , C07K16/18 , C07K16/40
CPC classification number: C07K16/40 , A61K9/08 , A61K9/19 , A61K31/198 , A61K31/401 , A61K31/4172 , A61K38/05 , A61K39/3955 , A61K39/39591 , A61K47/183 , A61K47/26 , C07K5/06 , C07K16/18
Abstract: Provided herein are excipients capable of effectively reducing the viscosity of polypeptide (e.g., therapeutic polypeptide) formulations. The viscosity reducing excipients are dipeptides containing arginine at the carboxy terminus and N-acetylated serine or N-acetylated proline at the N-terminus. Glutamate-arginine is also disclosed as a viscosity-reducing dipeptide. Among the disclosed methods, methods of reducing the viscosities of such formulations are also provided.
-
公开(公告)号：US11993663B2
公开(公告)日：2024-05-28
申请号：US17346156
申请日：2021-06-11
Applicant: AMGEN INC.
Inventor： Joon Hoi Huh , Riki Stevenson , Pavel Bondarenko , Andrew Nichols , Da Ren , Neeraj Jagdish Agrawal , Richard Smith
CPC classification number: C07K16/40 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/90 , C07K2317/92 , C07K2317/94 , G01N11/14
Abstract: The present invention concerns a method for preparing antigen binding proteins specific for PCSK9 with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
-
公开(公告)号：US11248043B2
公开(公告)日：2022-02-15
申请号：US16919032
申请日：2020-07-01
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish Agrawal , Kevin Graham , Agnes Eva Hamburger , Christopher Mohr , Derek E. Piper , Kenneth William Walker , Zhulun Wang , Cen Xu
IPC: G01N33/53 , A61K39/395 , A61K39/00 , A61K49/00 , A61K49/16 , C07K16/00 , C12P21/08 , C07K16/18 , C07K16/28 , A61P25/06 , A61K38/22 , A61K47/68 , A61K38/17 , A61K51/10 , C07K14/575 , C07K16/26 , C07K14/72 , C07K14/47 , G01N33/74 , G01N33/68
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
Patent Agency Ranking
公开(公告)号：US10738110B2
公开(公告)日：2020-08-11
申请号：US16246326
申请日：2019-01-11
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish Agrawal , Kevin Graham , Agnes Eva Hamburger , Christopher Mohr , Derek E. Piper , Kenneth William Walker , Zhulun Wang , Cen Xu
IPC: C07K16/00 , A61K39/395 , A61K39/00 , C12P21/08 , A61K49/00 , A61K49/16 , G01N33/53 , C07K16/18 , C07K16/28 , A61P25/06 , A61K38/22 , A61K47/68 , A61K38/17 , A61K51/10 , C07K14/575 , C07K16/26 , C07K14/72 , C07K14/47 , G01N33/74 , G01N33/68
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20190270817A1
公开(公告)日：2019-09-05
申请号：US16245733
申请日：2019-01-11
Applicant: AMGEN INC.
Inventor： Khaled M.K.Z. Ali , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Ian Foltz , Zhulun Wang , Daren Bates , Marissa Mock , Shunsuke Takenaka
Abstract: Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.
-
公开(公告)号：US11976103B2
公开(公告)日：2024-05-07
申请号：US17065395
申请日：2020-10-07
Applicant: Amgen Inc.
Inventor： Eric Alan Butz , Christy Ann Thomson , Marc Alain Gavin , Ian Nevin Foltz , Dong Xia , Dina N. Alcorn , Randal Robert Ketchem , Ai Ching Lim , Kathy Manchulenko , Laura Sekirov , Kelly Ann Berry , Cyr Clovis Chua De Imus , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Li Li
CPC classification number: C07K14/55 , A61K38/2013 , A61P37/00 , C07K16/246 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US11891435B2
公开(公告)日：2024-02-06
申请号：US17558032
申请日：2021-12-21
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish Agrawal , Kevin Graham , Agnes Eva Hamburger , Christopher Mohr , Derek E. Piper , Kenneth William Walker , Zhulun Wang , Cen Xu
IPC: C07K16/00 , A61K39/395 , A61K39/00 , A61K49/00 , A61K49/16 , C12P21/08 , G01N33/53 , C07K16/18 , C07K16/28 , A61P25/06 , A61K38/22 , A61K47/68 , A61K38/17 , A61K51/10 , C07K14/575 , C07K16/26 , C07K14/72 , C07K14/47 , G01N33/74 , G01N33/68
CPC classification number: C07K16/18 , A61K38/2278 , A61P25/06 , C07K16/2869 , A61K38/1796 , A61K38/22 , A61K47/6843 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/545 , A61K2300/00 , C07K14/47 , C07K14/575 , C07K14/57563 , C07K14/72 , C07K16/00 , C07K16/26 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/70 , C07K2317/72 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C12N2501/30 , G01N33/6854 , G01N33/6896 , G01N33/74 , G01N2333/575 , G01N2333/5757 , Y02A50/30
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US11541103B2
公开(公告)日：2023-01-03
申请号：US16054035
申请日：2018-08-03
Applicant: AMGEN INC.
Inventor： Khaled M. K. Z. Ali , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Ian Foltz , Zhulun Wang , Darren Bates , Marissa Mock , Shunsuke Takenaka
Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.02 seconds)
